2. Immunology/Inflammation
  3. Interleukin Related
  4. Secukinumab

Secukinumab  (Synonyms: AIN457)

製品番号: HY-P9927 純度: 98.9%
COA Technical Support

Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1229022-83-6

容量 価格（税別） 在庫状況 数量
1 mg $180 在庫あり
5 mg $620 在庫あり
10 mg $990 在庫あり
25 mg $1850 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 8 publication(s) in Google Scholar

Secukinumab Featured Recommendations:

Secukinumab 関連抗体

Top Publications Citing Use of Products

    Secukinumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 22;16(1):6753.  [Abstract]

    The growth curve showed Secukinumab (IL-17a inhibitor, 0.0375-1.5 μg/mL; 48 h) had no impact on mouse tongue muscle cells (mTMCs), mouse tongue squamous cell carcinoma (mTSCC) cells and CaL27 cells proliferation.

    Secukinumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 22;16(1):6753.  [Abstract]

    Detecting the mRNA level of Desmin for skeletal marker, Col1a1, PDGFRβ, Vimentin and fibroblast activated protein (FAP) for CAFs marker by qRT-PCR to determine the optimal concentration of Secukinumab (0.075-1.5 μg/mL; 48 h) treated.

    Secukinumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 22;16(1):6753.  [Abstract]

    Representative H&E staining displayed the tumor size in saline-treated TSCC (n = 3 mice/group) and Secukinumab (10 mg/kg; i.p.; once weekly for 5 weeks)-treated TSCC (n = 3 mice/group, left panel). The tumor boundary is marked by black dashed lines. Scale bar = 100 μm. The results showed that Secukinumab significantly impeded tumor growth, resulting in markedly smaller tumor volumes.

    Secukinumab purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 May 15:770:152031.  [Abstract]

    CCK-8 assay for cell viability in MDA-MB-231 cells treated with si-NC, si-KIF20A, si-KIF20A + rhIL-17A (100 μg/L), or Secukinumab (10 μg/mL). RhIL-17A treatment rescued cell viability in si-KIF20A cells, while Secukinumab alone significantly reduced viability compared to si-NC.

    Secukinumab purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 May 15:770:152031.  [Abstract]

    The proliferation level of MDA-MB-231 cells was determined by the Edu staining assay (scale bars = 100 μm). RhIL-17A restored EdU-positive cell numbers in si-KIF20A cells, whereas Secukinumab (10 μg/mL; 24 h) decreased proliferation.

    Secukinumab purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 May 15:770:152031.  [Abstract]

    The migration of MDA-MB-231 cells was detected by wound healing assay (scale bars = 50 μm). si-KIF20A + rhIL-17A exhibited increased wound closure compared to si-KIF20A, while Secukinumab (10 μg/mL; 24 h)-treated cells showed reduced migration.

    Secukinumab purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 May 15:770:152031.  [Abstract]

    Transwell invasion assay (scale bars = 50 μm). RhIL-17A reversed the si-KIF20A-mediated reduction in invasive cells, and Secukinumab (10 μg/mL; 24 h) alone suppressed invasion similarly to si-KIF20A.

    Interleukin Related アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis[1][2].

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target[1]

    IL-17A

     

    体外実験

    Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A[2].
    Secukinumab (1 nM, 10 nM, and 100 nM) inhibits IL17A and IL17A/TNF a-induced increase in protein levels of IL6 in human astrocytes[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Secukinumab 関連抗体
    臨床実験
    Gene ID

    3605  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    分子量

    147.82 kDa

    CAS 番号
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Secukinumab]
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    保管条件

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Immobilized IL-17A Protein, Human (HEK293, His, HY-P70527) can bind Secukinumab. The EC50 for this effect is 16.2 ng/mL.
    • Flow cytometric analysis of 1X106 Jurkat cells with Secukinumab (HY-P9927, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
    純度とドキュメンテーション

    純度: ≥99.20%

    COA (232 KB)

    Inhibitory Antibodies User Guide (603 KB)
    参考文献
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Secukinumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Secukinumab1229022-83-6AIN457AIN 457AIN-457Interleukin RelatedILpsoriasisfirst-in-classselectiveneutralizesinterleukinarthritisInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Secukinumab
    製品番号:
    HY-P9927
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.